A new multicentre study investigating PuraStat efficacy, safety, and ease of use for haemostasis in endonasal surgery (turbinate reduction, septoplasty and FESS).

Bleeding is a common intraoperative and/or post-operative issue in Endoscopic Endonasal Surgery...

Notice regarding the Conclusion of an Agreement Concerning Manufacturing License with FUSO Pharmaceutical Industries, Ltd.

3-D Matrix, Ltd. (headquarters: Chiyoda-ku, Tokyo; President and Representative Director: Jun...

US Notice Regarding Marketing Approval for Radiation Proctitis Wound Healing Material

We are pleased to announce that the 510K submitted to the United States Food and Drug...

3-D Matrix ranked in the Top 500 Fastest Growing Companies in Asia-Pacific region published by Financial Times

We are pleased to share that 3-D Matrix has been ranked 179th on the list of the 500...

Notice regarding the submission for new manufacturing process for haemostatic products in Europe

We are pleased to announce that on the 13th January 2022, our European subsidiary 3-D Matrix Europe...

Global news: Japan Published Their First PuraStat Case Report

Last month, the first PuraStat case report in Japan was published. Written by Dr Takuto Hikichi (...

RCT Study: Exploring Efficacy of PuraStat in EMR Surgeries Goes Live

The clinical trial ‘Colorectal EMR & Delayed Bleeding: Prospective multicentre randomised...

PuraStat: The Impact on Patient Care Now and the Future

On Wednesday 20th October 2021, 3-D Matrix (in partnership with FUJIFILM) hosted its biannual...

Global News: Approval of PuraStat for NHI Reimbursement

PuraStat, absorbable haemostatic material, has been approved for the listing on Japan’s National...

Global News: FDA clears hydrogel PuraStat-OM^®, a treatment for oral mucosa wounds

3-D Matrix, Inc., the U.S. subsidiary of 3-D Matrix group, obtained 510(k) clearance the pre-market...